This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Leerink Swann Global Healthcare Conference, being held February 13-14, 2013, at the Waldorf Astoria in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Thursday, February 14 at 11:00 AM (ET). Mr. Christensen will provide a corporate update regarding the Company’s key value drivers – KALBITOR
® (ecallantide) and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at
www.dyax.com. The webcast will also be available on the Dyax website for a limited period of time following the conferences.
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key value drivers are the KALBITOR
® (ecallantide) business and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).
Dyax developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others.
The Company is currently developing products to expand its angioedema portfolio, including diagnostic strategies to identify plasma kallikrein (bradykinin) mediated (PKM) angioedema and a therapeutic candidate, DX-2930, for the prophylactic treatment of, HAE and other PKM angioedemas.
KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 12 royalty and/or milestone bearing product candidates in various stages of clinical development, including three in Phase 3 trials.